WO2011031986A1 - Dosages du récepteur soluble à il-15 alpha - Google Patents

Dosages du récepteur soluble à il-15 alpha Download PDF

Info

Publication number
WO2011031986A1
WO2011031986A1 PCT/US2010/048451 US2010048451W WO2011031986A1 WO 2011031986 A1 WO2011031986 A1 WO 2011031986A1 US 2010048451 W US2010048451 W US 2010048451W WO 2011031986 A1 WO2011031986 A1 WO 2011031986A1
Authority
WO
WIPO (PCT)
Prior art keywords
sample
soluble
antibody
complex
amount
Prior art date
Application number
PCT/US2010/048451
Other languages
English (en)
Inventor
Jing Chen
Thomas Alexander Waldmann
Original Assignee
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health filed Critical The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Office Of Technology Transfer, National Institutes Of Health
Publication of WO2011031986A1 publication Critical patent/WO2011031986A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5443—IL-15
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/285—Demyelinating diseases; Multipel sclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the present invention generally relates to cytokine receptors, and more specifically to assays for detecting soluble interleukin-15 receptor alpha (IL-15Ra).
  • IL-15Ra soluble interleukin-15 receptor alpha
  • Interleukin-15 is a proinflammatory cytokine that shares several biological functions with interleukin-2 (IL-2).
  • IL-2 interleukin-2
  • both cytokines stimulate the proliferation of T cells; induce the generation of cytotoxic T lymphocytes; stimulate B cell proliferation and immunoglobulin synthesis; and induce the generation and persistence of natural killer (NK) cells.
  • NK natural killer
  • IL- 15 In addition to this shared receptor, IL- 15 also has a private receptor, IL- 15Ra. IL-
  • IL-15Ra binds to IL- 15 with far greater affinity for IL- 15 than IL-2 has for its private receptor, IL-2Ra. Soluble IL-15Ra is believed to be released by activated T cells by proteolytic shedding and retains its high affinity for IL- 15.
  • IL-15 also has functions that are distinct from, and at times competitive with, IL-2. These differences may be due, at least in part, to their private receptors.
  • IL-15 is not a secreted molecule but acts as a cell surface molecule during an immunological synapse.
  • IL- 15 bound to IL- 15R alpha on antigen presenting cells is presented in trans to target NK and CD8 T cells that only express the IL-2/IL-15 Receptor beta and common gamma chain of the multi-subunit receptor (Immunity. 2002: 17(5):537-47).
  • IL-2 has a unique role in activation-induced cell death (AICD), a process by which fully activated T cells undergo programmed cell death in response to certain cell surface-expressed death receptors such as FAS or TNF receptors, and participates in the maintenance of peripheral CD4 + CD25 + regulatory T cells.
  • AICD activation-induced cell death
  • IL-2 is involved in the elimination of self-reactive T cells, which have roles in the pathogenesis of autoimmune diseases.
  • IL-15 is important for the maintenance of long-lasting, high-avidity T-cell responses to invading pathogens by supporting the survival of CD8 + memory T cells and is also known to inhibit AICD.
  • IL-2 " and IL-2R “ ' mice showed lymphoid proliferation associated with autoimmune disorders, while IL-15 "7” and IL- 15Ra _/” mice showed normal total T and B cell populations, but profound defects in NK cells, NK-T cells, intraepithelial lymphocytes and CD8 + memory cells.
  • IL-15 has potential as an immunotherapeutic agent for cancer treatment because of its critical role in the proliferation and activation of NK and CD8 + T cells.
  • IL-15 overexpression has also been reported.
  • the upregulation of IL-15 has been implicated in several disorders, including arthritides, connective tissue disorder, ophthalmological disorders, neurological disorders, gastrointestinal and hepatic disorders, allergic disorders such as asthma, hematologic disorders, skin disorders, pulmonary disorders, malignancies, transplantation-related disorders, endocrinologic disorders, vascular disorders, gynecological disorders and infectious diseases.
  • IL-15 and IL-15Ra are co-expressed in association with a number of autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, chronic liver disease, refractory celiac syndrome, a disease associated with the development of enteropathy associated CD8 T-cell lymphoma.
  • sIL-15Ra can be used as a surrogate marker to determine the efficacy of cancer therapy agents or IL-15 receptor-inducing agents (such as LPS and interferon), or to identify patients who would be good candidates for certain IL-15 therapies.
  • IL-15Ra soluble IL-15Ra
  • radioimmunoassays have been used to detect IL-15Ra.
  • Mortier et al. Natural, Proteolytic Release of a Soluble Form of Human IL-15 Receptor a-Chain that Behaves as a Specific, High Affinity IL-15 Antagonist, J. Immunology 173: 1681-1688 (2004), describes the measurement of sIL-15Ra using a sandwich
  • radioimmunoassay in which a polyclonal goat anti -human IL- 15Ra antibody was used as the capture antibody and a radio-iodinated monoclonal anti -human IL-15Ra antibody was used as the detection antibody.
  • An assay sensitivity of about 1 pM was achieved using a recombinant IL-15Ra-IL-2 fusion protein as the assay standard.
  • Badoual et al. The Soluble a Chain ofInterleukin-15 Receptor: A
  • Enzyme-linked immunosorbent assays for murine soluble IL-15Ra have been developed, but lack the desired sensitivity.
  • a sandwich ELISA with a detection limit of 20 pg/ml of recombinant IL-15Ra in cell culture media is reported in Budagian et al., Natural Soluble Interleukin-l 5Ra is Generated by Cleavage That Involves the Tumor Necrosis Factor-a-converting Enzyme (TACE/ADAMl 7), J. Biol. Chem. 279(39):40368-40375.
  • IL-15-IgG was used as the capture protein, with biotinylated anti-mouse IL-15Ra antibodies used for detection. Serial dilutions of murine recombinant IL-15Ra were used as assay standards. Mortier et al., IL-15Ra Chaperones IL-15 to Stable Dendritic Cell Membrane Complexes that Activate NK Cells via Trans Presentation, J. Exp. Med.
  • the R&D IL-15Ra DuoSet product literature describes a typical indirect sandwich ELISA in which a goat anti-mouse IL-15Ra antibody is used as the capture antibody to bind sIL-15Ra in a sample, which in turn is bound by biotinylated goat anti-mouse IL-15Ra antibody as the detection antibody.
  • a recombinant mouse IL-15Ra/Fc chimeric protein is used as the assay standard, with no specified detection limit.
  • the present invention satisfies this need and provides related advantages as well.
  • One aspect of the present invention relates to the novel discovery of a sensitive and specific assay for quantifying low levels of soluble IL-15Ra in a sample.
  • the method is generally accomplished by the steps of:
  • test samples can include biological samples such as serum, plasma, tissue lysate, tumor lysate, or tumor cell culture supernatant.
  • biological samples can be obtained from a mammal, including humans.
  • the capture reagent that selectively binds sIL-15Ra is preferably an anti-IL-15Ra antibody, including monoclonal and polyclonal antibodies.
  • IL-15 can be obtained from any source, human IL-15 is particularly useful to assay samples containing human sIL-15Ra.
  • the detectable ligand is preferably an anti-IL-15 antibody. Suitable anit-IL-15 antibodies are monoclonal or polyclonal antibodies that selectively bind IL-15, but not IL-15Ra or the capture reagent.
  • the detectable ligand can be directly or indirectly labeled.
  • the ligand can be directly labeled with a colorimetric reagent, or indirectly labeled using biotin and avidin or streptavidin- alkaline phosphatase as the detection means.
  • the methods of the present invention are particularly suitable for the enzyme-linked immunosorbent assay (ELISA) format.
  • soluble IL-15Ra (sIL-15Ra) in a sample is quantified with the use of a standard curve produced using pre-determined quantities of an IL-15Ra protein.
  • the IL-15Ra is an IL-15Ra-IL-2 chimeric protein having full length extracellular domains of IL-15Ra and IL-2.
  • a novel IL-15Ra-IL-2 chimeric protein having an amino acid sequence of SEQ ID NO:6 is also provided.
  • the methods of the present invention are capable of quantifying less than about 20 pg/ml of sIL- 15Ra in a sample, preferably less than about 7 pg/ml, and more preferably at least about 1 pg/ml.
  • kits for carrying out the present methods contain a capture reagent that selectively binds sIL-15Ra, IL-15, a detectable ligand that selectively binds IL-15 and a means for measuring the amount of sIL-15Ra in the sample.
  • the kits can also include a reference standard, a standard curve for IL- 15Ra and any ancillary reagents and components for carrying out the methods of the present invention.
  • IL-15Ra-associated disorders can be leukemia (e.g., adult T cell leukemia, T-cell large granular lymphocyte (LGL) leukemia, Natural killer cell leukemia), lymphoma (e.g., adult T cell leukemia/lymphoma), autoimmune disease (e.g., type I diabetes, celiac disease, HTLV-I- associated myelopathy/tropical spastic paraparesis (HAM/TSP), rheumatoid arthritis or multiple sclerosis), retroviral disease, or LPS induced septic shock.
  • leukemia e.g., adult T cell leukemia, T-cell large granular lymphocyte (LGL) leukemia, Natural killer cell leukemia
  • lymphoma e.g., adult T cell leukemia/lymphoma
  • autoimmune disease e.g., type I diabetes, celiac disease, HTLV-I- associated myelopathy/tropical spastic parapare
  • a further aspect of the invention relates to methods for monitoring the effectiveness of a therapeutic treatment that increases the amount of sIL-15Ra in a patient, comprising measuring the amount of soluble IL-15Ra in a sample from the patient.
  • These methods are particularly useful when therapeutic treatment is LPS, interferon, IL- 15 or IL- 15Ra.
  • Fig. 1 illustrates the basic assay format of the present invention.
  • Fig. 2 shows typical data obtained for an IL-15Ra standard curve using the IL-15Ra- IL2 chimeric protein as the reference standard.
  • Fig. 3 shows the neutralizing activity of sIL-15Ra-IL2 chimeric protein on IL-15 in CTLL-2 cell assays.
  • Fig. 3A shows that the chimeric protein maintains the biologic activity of IL2 in the assays.
  • Fig. 3B shows that IL-15Ra-IL2 blocks the biologic activity of IL-15 when bound to IL- 15.
  • Fig. 4 shows that IL-15Ra was detected in the supernatant of (A) PT18 and (B) 293T cells transfected with wildtype IL-15Ra and/or soluble IL-15Ra.
  • Fig. 5 shows that the soluble IL-15Ra expressed by transfected cells was not detected by Western blot because the soluble IL-15Ra was secreted into the supernatant as shown in Fig. 3.
  • Fig. 10 shows elevated serum level of sIL-15Ra in HTLV-I-associated
  • Fig. 14 shows that the serum level of sIL-15Ra is not elevated in CSF and other neuroimmunological disorders.
  • Fig. 15 shows the DNA and amino acid sequences for the full IL15Ra-IL2 chimeric protein.
  • the present invention generally relates to assays that are sensitive and specific for soluble IL-15Ra.
  • the terminology used herein is for the purpose of describing particular embodiments and is not intended to be limited to such embodiments.
  • the singular forms of "a”, “an” and “the” also include the plural, and vice versa, unless expressly limited otherwise by the context.
  • the terms “having,” “containing,” “including” and the like are used interchangeably to mean “comprising,” “consisting essentially of or “consisting of as those patent terms of art are typically defined.
  • each publication, patent or other reference disclosed herein is hereby incorporated by reference in its entirety.
  • the methods of the present invention are based, in part, on the discovery that lower amounts of IL-15Ra in a sample can be measured (i.e., improved assay sensitivity) using IL- 15 as a component of the assay.
  • Figure 1 illustrates the basic assay format of the present invention. Generally, the methods of the present invention can be accomplished by:
  • the assays of the present invention can be carried out using a variety of methods known in the art, including, without limitation, Western blot, immunoblot, enzyme- linked immunosorbant assay (ELISA), radioimmunoassay (RIA), or immunohistochemical analysis
  • ELISA enzyme- linked immunosorbant assay
  • RIA radioimmunoassay
  • the ELISA format is particularly useful for its simplicity and use of non-hazardous materials. Therefore, when the ELISA format is used to describe the present invention, it is done so solely for illustrative purposes. Those skilled in the art can readily determine, without undue experimentation, appropriate steps and reagents for the other assay formats based on the teachings provided herein.
  • a sample first comes into contact with the capture reagent for a sufficient period of time to allow soluble IL-15Ra to bind to the capture reagent.
  • capture reagent refers to any reagent capable of forming a complex with IL-15Ra.
  • a capture reagent includes, but is not limited to, a protein, peptide or other antigen binding partner that selectively binds to IL- 15Ra or a mixture thereof.
  • the term “selectively binds to” or the like refers to the specific binding of a target protein (e.g., IL-15Ra) to an antigen binding partner (e.g., an antibody, antibody fragment or other non-antibody binding partner), wherein the level of binding, as measured by any standard assay known to those skilled in the art (e.g., an immunoassay), is statistically and significantly higher than the background control for the assay or for other non-target proteins.
  • a target protein e.g., IL-15Ra
  • an antigen binding partner e.g., an antibody, antibody fragment or other non-antibody binding partner
  • an antigen generally refers to any portion of a protein or peptide, cellular composition, organism or other moiety that elicits an antigen-specific immune response (humoral and/or cellular immune response).
  • an antigen can be IL-15Ra or any functional fragment thereof having an epitope capable of being selectively bound by a capture reagent.
  • An epitope can be defined by both the amino acid residues involved in the selective binding and by its three dimensional conformation. Therefore, an epitope can be included in peptides as small as 4-6 amino acid residues or in larger segments of non-contiguous amino acids that are brought together by protein folding into a three dimensional conformation.
  • antibody includes polyclonal and monoclonal antibodies, and any functional equivalents to whole antibodies that selectively bind to IL-15Ra.
  • Functional equivalents of whole antibodies such as antigen binding fragments in which one or more antibody domains are truncated or absent (e.g., Fv, Fab, Fab' or F(ab) 2 fragments), as well as genetically-engineered antibodies or antigen binding fragments are also included in the term
  • Antibodies useful in the present invention can be produced by any means or obtained from any source known to those skilled in the art. Suitable anti-IL-15Ra antibodies are also commercially available.
  • the capture reagents of the present invention are polyclonal or monoclonal antibodies.
  • Polyclonal antibodies include a population of different antibodies directed against different epitopes of a target antigen.
  • the production of polyclonal antibodies is well known in the art and typically involves the immunization of a suitable experimental animal, for example, a rodent, rabbit, sheep and the like, with a desired target antigen (e.g., IL-15Ra).
  • a desired target antigen e.g., IL-15Ra
  • An effective amount of the antigen is injected into the animal to induce antibody production, sometimes repeatedly over a period of time, until the animal is producing antibodies against the target antigen.
  • Serum, ascites or other bodily fluid or tissue known to contain antibodies is collected from the animal and can be used.
  • Such antibodies can also be purified to varying degrees.
  • monoclonal antibodies are highly specific for a single epitope of a target antigen.
  • Methods for producing monoclonal antibodies are well known in the art, including the method of Kohler and Milstein, Nature 256:495-497 (1975), in which B lymphocytes are recovered from the spleen of an immunized animal and fused with myeloma cells to obtain a population of hybridoma cells capable of continued growth in cell culture medium.
  • monoclonal antibodies can be made by recombinant DNA methods, such as described in U.S. Patent No.
  • Genetically-engineered antibodies include those produced by standard recombinant DNA techniques involving the manipulation and re-expression of DNA encoding antibody variable and/or constant regions.
  • the hypervariable region of an antibody refers to the amino acid residues from the complementarity-determining region ("CDR") that is responsible for antigen binding. Framework amino acid residues are located in the non-hypervariable region of the variable domain.
  • Examples of genetically-engineered antibodies include chimeric antibodies in which the V H and/or V L domains of the antibody come from a different source to the remainder of the antibody, and CDR grafted antibodies in which at least one CDR sequence and, optionally, at least one variable region framework amino acid, are derived from one source and the remaining portions of the variable and the constant regions are derived from a different source. Construction of chimeric and CDR-grafted antibodies are well known in the art and are described, for example, in U.S. Patent No. 5, 859,205.
  • the capture reagents can also be non-antibody binding partners or antigen binding peptides that have been designed to selectively bind to IL-15Ra.
  • the design of non-antibody binding partners are generally described in Beste et al., Proc. Natl. Acad. Sci., 96: 1898-1903 (1993).
  • the capture reagent is immobilized on a solid support or carrier that is essentially insoluble in an aqueous solution.
  • Suitable solid supports and carriers include, without limitation, those described in U.S. Patent Publication No. 2008/02271 19, such as beads, plates, tubes, sheets, porous matrices made of
  • a multi-well microtiter plate is particularly useful to analyze several samples at one time.
  • the capture antibody is attached to the solid support by any means known to those skilled in the art, including the means described in U.S. Patent Publication No. 2008/02271 19 for covalent, non-covalent and physical attachment.
  • the concentration of the capture reagents can be determined by the concentration range of interest and is typically determined experimentally to maximize the sensitivity of the assay for soluble IL-15Ra.
  • the concentration range for an anti-IL-15Ra antibody is typically about .05 ug/ml to about 50 ug/ml, preferably about .05 ug/ml to about 20 ug/ml, and more preferably about 10 ug/ml.
  • Multi-well plates typically used in ELISAs, can be coated with the capture reagent diluted in a suitable dilution buffer, such as 0.05 M sodium carbonate at a pH between 8-12, preferably between 9-10, and usually incubated between 2 hours to overnight at 4°- 25° C.
  • a suitable dilution buffer such as 0.05 M sodium carbonate at a pH between 8-12, preferably between 9-10, and usually incubated between 2 hours to overnight at 4°- 25° C.
  • the coated wells can be used immediately or stored for a long period of time before used in the present assays.
  • the coated plates can be washed one or more times with a suitable washing buffer known to those skilled in the art prior to being treated with a blocking agent.
  • a blocking agent binds non-specifically to and saturates the binding sites on a solid support to prevent unwanted binding of the soluble IL- 15Ra to sites other than on the capture reagent.
  • Suitable blocking agents include, for example, bovine serum albumin (BSA), gelatin, egg albumin, casein and non-fat milk.
  • BSA bovine serum albumin
  • the blocking treatment is usually done from about 25°- 37° C for about 1-4 hours or overnight at about 0°-4° C.
  • the coated wells are preferably washed with washing buffer to remove any excess blocking agent.
  • sample and “test sample” are used interchangeably to refer to a sample of any type that contains or is suspected of containing soluble IL-15Ra.
  • a test sample can be obtained from a natural source or synthetically produced.
  • a sample can therefore include cell culture supernatant, biological sample, buffer or other media that contains or is suspected of containing IL-15Ra.
  • the sample can include a reference standard for obtaining a standard curve for accurately measuring the quantity of IL-15Ra.
  • Biological samples suitable for use as samples in the present methods include, without limitation, blood, serum, plasma, tissue lysates, tumor lysates and the like that are obtained from a test subject.
  • test subject and “patient” are used interchangeably herein and refer to any mammal capable of expressing IL-15Ra, for example, humans, non-human primates, domestic, research or farm animals such as rodents, dogs, cats, horses, sheep, pigs, and cows.
  • the methods of the present invention are particularly useful when the test subject is a human.
  • the sample can be diluted in a suitable sample buffer, which can be readily selected by those skilled in the art.
  • suitable sample buffers include, without limitation, borate, phosphate, carbonate, Tris-HCL and Tris-phosphate.
  • a suitable sample buffer can also be selected to maintain a desired pH during the incubation in order to maximize the binding between the capture reagent and any soluble IL-15Ra in the sample.
  • the buffer has a pH in the range of about 6-9.
  • a pH in a range from about 7-8 is particularly useful, and preferably about 7.4.
  • Other reagents can be included in the sample buffers, including, for example, bovine serum albumin, stabilizers, preservatives, detergents, surfactants and the like.
  • the sample can be incubated with the immobilized capture reagent at a fairly constant temperature ranging from about 0° -40° C.
  • the incubation time will primarily depend on the incubation temperature, with time decreasing as temperature increases. For example, a sample can be incubated overnight at 4° C, but only about 1-3 hours at room temperature to maximize sensitivity and to minimize disassociation.
  • the incubation time can be increased if a protease inhibitor is added to prevent proteases in a biological sample from degrading IL-15Ra. Suitable protease inhibitors are well known to those skilled in the art.
  • a measurable amount of soluble IL-15Ra will be complexed to the capture reagents if present in the sample.
  • the sample Prior to the addition of IL-15, the sample is optionally washed with a suitable washing buffer one or more times to separate bound IL- 15Ra from the remaining sample.
  • a cross-linking agent can be added, if desired, to allow the bound IL- 15Ra to be covalently attached to the capture reagent to inhibit disassociation during the remaining steps of the assay.
  • IL-15 is added to the assay.
  • ELISAs for soluble IL-15Ra have only attained a sensitivity of about 20 pg/ml, compared to the present methods, which are able to achieve a significantly improved sensitivity as discussed below.
  • radioimmunoassays have achieved a sensitivity of about 1 pM, but only with the use of hazardous reagents, such as radioisotopes.
  • IL-15 includes wild-type IL-15 and functional equivalents of IL-15.
  • functional equivalents of IL-15 includes homologues, variants, muteins and active fragments of IL-15 having similar or increased affinity for IL-15Ra compared to wild- type IL-15.
  • IL- 15 for use in the methods of the present invention.
  • human IL-15 is preferred, with recombinant human IL-15 being most preferred.
  • Methods for obtaining or producing IL-15 are well known in the art, including, without limitation, isolating IL-15 from a naturally-occurring source, by recombinant DNA methods, or by chemical synthesis.
  • the IL-15 can be diluted in a suitable buffer solution as described above.
  • Such buffer solutions can include suitable amounts of other reagents, such as BSA, detergents, stabilizers, preservatives, surfactants and the like to increase the binding of IL-15 to IL-15Ra bound to the capture reagent.
  • Useful concentrations of IL-15 can be determined by the concentration range of interest and is typically determined experimentally to maximize the sensitivity of the assay for IL-15Ra.
  • the concentration of IL-15 is in the range of about 50 ng/ml to about 500 ng/ml in an ELISA, with a concentration of about 200 ng/ml being preferred when recombinant human IL-15 is used.
  • the IL-15 is incubated at a temperature and for a period of time sufficient for the IL-15 to bind the IL-15Ra bound to the immobilized capture reagent, thus forming a complex of IL-15, IL-15Ra and capture reagent (referred to herein as the "second complex").
  • the IL-15 is incubated at a temperature between about 20° -40° C, preferably about 37° C, for a period of about 1-3 hours, preferably about 1 hour.
  • the wells are again washed one or more times with a suitable wash buffer as described above to remove any unbound IL-15.
  • the wash buffer is removed completely before proceeding to the next step.
  • detectable ligand refers to a protein, peptide or other antigen binding partner that selectively binds to IL-15 or a mixture thereof and is capable of being directly or indirectly detectable. Ideally, useful ligands should not bind IL-15Ra or the capture reagent.
  • Particularly useful ligands of the present invention include polyclonal and monoclonal antibodies specific for IL-15.
  • the methods of obtaining and making anti-IL-15Ra antibodies as described above are generally applicable for obtaining anti-IL-15 antibodies. Additional anti-IL-15 antibodies and various methods of making the same are also described in U.S. Patent No. 7,329,405.
  • the ligands can also be non-antibody binding partners or antigen binding peptides that have been designed or selected to selectively bind to IL-15.
  • the design of non-antibody binding partners are generally described in Best et al., supra.
  • the ligands can be made detectable by the use of a label that does not interfere with the binding of IL- 15Ra to the capture reagent, the binding of IL- 15Ra to IL- 15 or the binding of IL- 15 to the detectable ligand.
  • Suitable labels for use in the present invention are well known to those skilled in the immunoassay art, including labels that can be detected directly, such as fluorochrome and chemiluminscent labels for example, or indirectly, such as enzymes that must be reacted or derivatized to be detected.
  • suitable radioisotope labels and methods of using them as labels are well known in the art.
  • fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luceriferases, luciferin, 2,3- dihydrophthalazinediones, horseradish perioxidase (HRP), alkaline phosphatase, ⁇ - galactosidase, gluconamylase, lysozyme, saccharide oxidases such as glucose oxidase, galactose oxidase and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that uses hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperioxidase or microperioxidase, biotin/avidin, biotin/streptavidin, biotin/Streptavidin- -gal
  • the ligand is biotinylated and the detection means is streptavidin alkaline phosphatase and 4-nitrophenyl phosphate disodium salt in a diethanolamine buffer.
  • Methods for attaching labels to the ligands are well known in the art.
  • the ligands can be coupled to the fluorescent, chemiluminescent and enzyme labels using coupling agents such as dialdehydes, carbodiimides, dimaleimides, bis-imidates, bis- diazotized benzidine and the like as described in U.S. Patent Publication No. 2008/0227119 and the references cited therein.
  • the detectable ligand is contacted (i.e., incubated) with the second complex at a temperature and for a period of time that are dependent on the ligand and label used.
  • the incubation temperature is between about 20°-40° C and the incubation period is about 1 hour or more to amplify the signal.
  • a temperature of about 37° C with an incubation period of about 1 hour are preferred when streptavidine alkaline phosphatase and 4-nitrophenyl phosphate are used as the detection means.
  • Excess or unbound labeled ligand is preferably removed by one or more washings with a suitable wash buffer as described above.
  • the amount of once soluble IL-15Ra, but now sandwiched between the capture reagent and IL-15, which in turn is bound to the detectable ligand, is measured.
  • the amount of soluble IL-15Ra is quantified by comparing the results with a standard curve obtained by conducting the same immunoassay with known concentrations of a IL-15Ra reference standard.
  • An IL-15Ra standard curve can be used, for example, to compare the level of soluble IL-15Ra in a sample taken from a patient with that of a normal individual.
  • Suitable IL-15Ra reference standards include isolated and purified IL-15Ra, fusion proteins in which IL-15Ra is fused to a second protein or polypeptide, or chimeric IL-15Ra proteins in which a suitable protein or peptide can be linked by recombinant technology to increase the sensitivity of the assay.
  • Suitable reference standards for the assays of the present invention can be readily determined by those skilled in the art without undue experimentation, including, for example, the IL-15Ra proteins described in U.S. Patent Publication Nos. 2009/0018316 and 2008/0255039.
  • picomolar amounts may distinguish a patient suffering from a certain disorder associated with an increase or decrease of soluble IL- 15Ra compared to a normal individual.
  • the inventors discovered that the sensitivity of the present assays can be improved significantly using an IL- 15Ra-IL-2 chimeric protein containing the full length extracellular domain of IL-15Ra as the reference standard compared with a commercially available soluble IL- 15Ra-Ig fusion protein in which exon 3 has been deleted from IL-15Ra. The deletion of exon 3 has been shown to reduce the affinity of the IL-15Ra to IL-15.
  • Figure 2 shows a typical standard curve using a novel IL- 15Ra-IL-2 chimeric protein as the reference standard. This chimeric protein was produced in accordance with Example 2 below.
  • the methods of the present invention are capable of accurately measuring at least about 20 pg/ml, at least about 19 pg/ml, at least about 18 pg/ml, at least about 17 pg/ml, at least about 16 pg/ml, at least about 15 pg/ml, at least about 14 pg/ml, at least about 13 pg/ml, at least about 12 pg/ml, at least about 1 1 pg/ml, at least about 10 pg/ml, at least about 9 pg/ml, at least about 8 pg/ml, at least about 7 pg/ml, at least about 6 pg/ml, at least about 5 pg/ml, at least about 4 pg/ml, at least about 3 pg/ml, at least about 2 pg/ml or at least about 1 pg/ml of soluble IL-15Ra in a sample.
  • the sensitivity at least about 20
  • ELISAs for other cytokines and cytokine receptors such as IL-2 (7 pg/ml; R& D Systems) and sIL-2Ra (10 pg/ml; R& D Systems).
  • kits containing at least the essential components for carrying out the present methods minimally include: (a) a capture reagent; (b) IL-15; and (c) a detectable ligand, all of which are described more fully above.
  • the kits also include reference standards and/or a standard curve for IL- 15Ra.
  • kits can also include a solid support for the capture reagents, in which the capture reagents are provided separately or immobilized on the solid support.
  • the kits can additionally include detection reagents for detecting the ligand.
  • the label is an enzyme
  • the kit can include substrates and any desired cofactors required by the enzyme.
  • the label is biotin
  • the kit can include an avidin or an avidin conjugate (e.g., streptavidin conjugated to alkaline phosphatase).
  • kits can also include any or all of the other reagents used in the methods of the present invention, including, among others, washing buffers, incubation buffers, stabilizers, preservatives, and detergents.
  • Such reagents can be in solution or can be lyophilized for later reconstitution (e.g., at the time of performing the assay).
  • the methods and kits of the present invention can be used to diagnose or monitor patients with various IL-15Ra-associated diseases. Therefore, the present invention further provides methods for diagnosing or monitoring a patient with an IL-15Ra-associated disorder by:
  • leukemia includes, without limitation, adult T cell leukemia, T-cell large granular lymphocyte (LGL) leukemia and natural killer cell leukemia.
  • “Autoimmune diseases” include, for example, type I diabetes, HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), celiac disease, rheumatoid arthritis, inflammatory bowel disease.
  • Retroviral diseases include, for example, HTLV and HIV and multiple sclerosis. The methods can also be used to monitor the effectiveness of IL-15 therapy or vaccination with IL- 15 or IL- 15Ra.
  • Soluble IL-15Ra can also be used as a surrogate marker for the effectiveness of LPS and interferon treatment.
  • methods for monitoring the effectiveness of LPS or interferon treatment are provided in which the amount of soluble IL- 15Ra is measured in a patient sample using the assays of the present invention, wherein the detection of an increased amount of soluble IL-15Ra in the sample, as compared to a control level of soluble IL-15Ra, indicates the treatment is effective in inducing immunity since LPS and interferon are known to induce expression of IL-15Ra.
  • an appropriate control e.g., a sample from a normal patient as a negative control or from a patient known to have the disorder as a positive control.
  • This example illustrates an ELISA for detecting soluble IL-15Ra in a sample.
  • IL15Ra Polyclonal anti-human IL15Ra (AF247, R&D Systems, Minneapolis, MN) was used as capture antibody.
  • Human IL15 was obtained from Peprotech Inc. (Rocky Hill, NJ; catalog No.200-15.
  • Anti-IL15 antibody was purified from mouse ascites (Harlan Bioproducts for Science Inc, Madison, WI), which were made from anti-human IL15 hybridoma (Ml 11, Genzyme, Cambridge, MA) and then labeled with biotin as described below.
  • ImmunoPureTM Streptavidin-alkaline phosphatase conjugated was purchased from Pierce Biotechnology
  • the substrate 4 Nitrophenyl phosphate disodium salt dexahydrate (N9389, Sigma, St. Louis, MO) was dissolved at lmg/ml into diethanolamine buffer (1M
  • IX wash buffer was made from wash buffer concentrate (WA126, R&D Systems).
  • BSA was purchased from sigma (A3803) and was dissolved into PBS (Invitrogen) at 3% (g/V). The plate was read at 405nm on SpectraMax 340PC (Molecular Device, Sunnyvale, CA). SoftMax was used for data analysis.
  • Monoclonal anti-IL15 was prepared in PBS and the concentration was measured using BCATM protein assay kit (Pierce Biotechnology). The volume of lOmM biotin reagent solution needed to add to the reaction was calculated by following the instructions provided with sulfo-NHS-LC-Biotin (21335, Pierce Biotechnology). Immediately before use, a lOmM biotin solution was prepared using ultrapure water. The calculated volume of lOmM biotin solution was added to the protein solution and incubate on ice for 2 hours. The protein solution was then dialyzed against PBS for 2 days to remove the free biotin. The
  • concentration of biotin labeled anti-IL15 antibody was then measured using BCATM protein assay kit.
  • substrate reagent by dissolve 4- Nitrophenyl phosphate disodium salt into Diethanolamine buffer at lmg/ml, incubate at 37°C and protect from light.
  • This example describes the production of the sIL15Ra -IL2 chimeric protein.
  • the sIL15Ra coding region including preprolactin signal peptide and Kozak sequence were amplified using primers 5 'ATTGAATTCGCCGCCACCATGGACAGC3 ' (SEQ ID NO: l) (sIL 15Ra sense primer) and 5 '
  • AGCCTGCAGATGTACAGGATGCAACTCC 3' (SEQ ID NO:3)(IL-2 sense primer) and 5 'GATGGATCCTCAAGTTAGTGTTGAGATGATGC3 '(SEQ ID NO:4)(IL-2 anti-sense primer).
  • the sIL15Ra-IL2 coding region was then amplified with sIL-15Ra sense primer and IL-2 anti-sense primer using sIL15Ra and IL2 coding regions as a template.
  • sIL15Ra-IL2 coding region and the expression plasmid pEF-neo were then digested with EcoRI and BamH 1 and then ligated using T4 DNA ligase (Roche Molecular Biochemicals, Indianapolis, IN).
  • DH5a competent cells (Invitrogen, Carlsbad, CA) were transformed with the ligation mixture and transformants containing the pEF-neo-sILl 5Ra- IL2 construct were selected.
  • To express sIL15Ra-IL2 chimeric protein 293T cells were transfected with pEF-neo-sIL15Ra-IL2. Culture supernatants were collected 72 hours after transfection by centrifugation and then filtered through 0.22um filter (Millipore, Bserverrica, MA).
  • the DNA sequence of the full IL15Ra-IL2 chimeric protein was determined to be as follows:
  • amino acid sequence of the full IL15Ra-IL2 chimeric protein was determined to be as follows:
  • This example provides the minimum detectable dose of sIL15Ra attained by ELISA.
  • Standard Curve The concentration of sIL15Ra-IL2 made from culture supernatant of 293T cell transfectants was measured using human IL-2 ELISA (R&D Systems) and converted to molar concentration.
  • sIL15Ra-IL2 was diluted into IX reagent diluents to obtain 60pM sIL15Ra-IL2. Two fold series dilutions were made in IX reagent diluents to obtain 30pM, 15pM, 7.5pM, 3.75pM, 1.875pM, 0.9375pM sIL15Ra-IL2.
  • the minimum detectable dose of sIL-15Ra is typically less than about 0.3 pM (equals 7 pg/ml).
  • the molecular weight of sIL-15Ra is 21 KD.
  • the minimum detectable dose was determined by adding two standard deviations to the mean optical density value of twenty zero standard replicates and calculating the corresponding concentration as shown in Table 2.
  • CTLL-2 cells were cultured with RPMI1640 plus 10%FBS, 200U/ml recombinant human IL-2 (TecinTM, NCI BRB preclinical repository) and 55uM 2-mercaptoethanol (Invitrogen, Carlsbad, CA). On the day of proliferation, CTLL-2 cells were washed 4 times with PBS, then resuspended in RPMI1640 plus 10%FBS at concentration of 10 6 cells/ml and use lOOul cells each well for proliferation.
  • sIL15Ra-IL2 To measure the biological activity of sIL15Ra-IL2, different concentrations of sIL15Ra-IL2 were added with or without lOug/ml monoclonal antibody to human IL2 (MAB202, R&D Systems) and cultured for 20 hours at 37°C. luCi 3 H thymidine (GE Healthcare Life Sciences, Piscataway, NJ) was added to each well 4 hours before harvesting and the cells were harvested on TomTec 96 well cell harvester (TomTec, Hamden, CT).
  • MAB202 human IL2
  • luCi 3 H thymidine GE Healthcare Life Sciences, Piscataway, NJ
  • sIL15Ra-IL2 To show the neutralizing activity of sIL15Ra-IL2 on IL15, different concentration of recombinant human IL15 (200-15, Peprotech Inc) or human IL15 with same molar concentration as sIL15Ra-IL2 and lOug/ml monoclonal anti-IL2(MAB202, R&D system) were added to washed CTLL-2 cells. The cells were cultured for 20 hours at 37°C. luCi 3 H thymidine was added to each well 4 hours before harvesting and the cells were harvested on TomTec 96 well cell harvester. The results are shown in Figure 3. As shown in Figure 3 A, IL-15Ra-IL2 maintains the biological activity of IL2 in the CTLL-2 assay. Figure 3B shows that IL-15Ra-IL2 blocks the biological activity of IL-15 through binding to IL-15.
  • Example 5 This example shows that expression of soluble IL-15Ra can be detected in the supernatants of transfected cells using the method of the present invention.
  • PT18 and PT18IL15Ra cells were cultured in RPMI1640 plus 10%FBS and lOng/ml murine recombinant IL-3 (R&D system) as reported (Tagaya Y et al, EMBO J. 1996, 15(18): 4928-493) . Culture supernatants from PT 18 and PT 18IL 15Ra were collected by
  • 293T cells (ATCC) were cultured in RPMI1640 plus 10%FBS. To transfect 293T cells, split cells 1 :4 the day before transfection. The transfection was performed according to the instructions of Fugene6 Transfection Reagent (Roche Molecular Biochemicals). For 10cm dish, dilute lOug pEF-neo, pEF-neo-WTIL15Ra or pEF-neo-sIL15Ra construct into lOOul Opti-MEMI medium (Invitrogen). Dilute 30ul of Fugene6 into lOOul Opti-MEMI medium.
  • This example describes the Western blot analysis of cells transfected with IL-15Ra.
  • PT18, PT18IL15Ra, 293T cells and 293T cells transfected with wild type IL15Ra and soluble IL15Ra were solubilized at 4°C in RIPA lysis buffer (50mM Tris-CL, pH7.4, 0.5% sodium deoxycholate, 1% Nonidet P-40, 150mM NaCl, 66 ⁇ g/ml aprotinin, 100 ⁇ g/ml phenylmethylsulfonyl fluoride, and 1 mM sodium orthovanadate).
  • Cell lysates (50 ⁇ g) were resolved by electrophoresis on SDS-polyacrylamide (4-12%) gels and transferred to polyvinyhdine difluoride membranes. After blocking of the membranes in 5% skim milk and 0.05% Tween 20 in Tris-buffered saline, the blots were incubated with goat polyclonal antibody to IL15Ra (SC-5526, Santa Cruz Biotechnology). After several washings with Tris-buffered saline plus 0.1% Tween 20, the blots were then incubated with HRP conjugated mouse anti-goat antibody(SC-2354, Santa Cruz Biotechnology, Santa Cruz, CA).
  • This example describes the results of a comparison between normal human serum and reagent diluents spiked with sIL-15Ra.
  • This example shows the levels of s sIL-15Ra in various serum samples from patients afflicted with various disorders.
  • Serum samples were diluted 1 :3 into IX reagent diluents and duplicates of lOOul diluted serum samples were assayed follow the general assay procedure of Example 1.
  • Serum samples from normal donors were collected from NIH blood bank (transfusion medicine, NIH).
  • Serum samples from type I diabetes patients were obtained from ProMedDx (Norton, MA). The results of Figure 7 show elevated levels of sIL-15Ra in serum type I diabetes patients compared to normal individuals.
  • Serum samples from Adult T cell leukemia patients, T-cell large granular lymphocyte (LGL) leukemia patients, HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP), Natural killer cell leukemia (NKL) were collected by metabolism branch, NCI/NIH.
  • LGL T-cell large granular lymphocyte
  • HAM/TSP HTLV-I-associated myelopathy/tropical spastic paraparesis
  • NCL Natural killer cell leukemia
  • Serum samples from multiple sclerosis (MS) and rheumatoid arthritis patients were purchased from Bioserve, with the results shown in Figures 12 and 13, respectively. As shown in Figure 12, there was no significant difference between the ⁇ -interferon treated MS patients and the untreated MS patients.
  • CSF and serum samples from neuroimmunological disorders were collected by Dr. Bibi Bielekova (NINDS/NIH). The results of the CSF and neuroimmunological disorders are shown in Figure 14.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un dosage sensible et spécifique permettant de quantifier de faibles taux d'IL-15Rα soluble dans n'importe quel échantillon de mammifère contenant ou présumé contenir sIL-15Rα, y compris des échantillons biologiques tels que du sérum, du plasma, un lysat tissulaire, un lysat de tumeur ou un surnageant de culture de cellules tumorales. Ces méthodes sont particulièrement appropriées pour un dosage immunoenzymatique (ELISA). L'invention concerne également des méthodes de diagnostic ou de surveillance de troubles associés à IL-15Rα-, notamment des leucémies, des lymphomes, des maladies auto-immunes, des maladies rétrovirales ou d'un choc septique induit par LPS. L'invention concerne également des méthodes de surveillance de l'efficacité d'un traitement thérapeutique qui augmente la quantité de sIL- 15Rα chez un patient, en particulier lorsque le traitement thérapeutique est LPS, un interféron, IL-15 ou IL-15Rα.
PCT/US2010/048451 2009-09-10 2010-09-10 Dosages du récepteur soluble à il-15 alpha WO2011031986A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24126509P 2009-09-10 2009-09-10
US61/241,265 2009-09-10
US24259509P 2009-09-15 2009-09-15
US61/242,595 2009-09-15

Publications (1)

Publication Number Publication Date
WO2011031986A1 true WO2011031986A1 (fr) 2011-03-17

Family

ID=42983831

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/048451 WO2011031986A1 (fr) 2009-09-10 2010-09-10 Dosages du récepteur soluble à il-15 alpha

Country Status (1)

Country Link
WO (1) WO2011031986A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311972A (zh) * 2016-06-15 2019-02-05 美国安进公司 用于治疗乳糜泻、非乳糜泻麸质敏感和难治性乳糜泻的方法和组合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591630A (en) 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US20080227119A1 (en) 2006-10-04 2008-09-18 Genentech, Inc. ELISA for VEGF
US20080255039A1 (en) 2004-02-27 2008-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Il-15 Binding Site for Il 15-Ralpha and Specific Il-15 Mutants Having Agonists/Antagonists Activity
US20090018316A1 (en) 1994-05-06 2009-01-15 Anderson Dirk M Interleukin-15 receptors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5591630A (en) 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US20090018316A1 (en) 1994-05-06 2009-01-15 Anderson Dirk M Interleukin-15 receptors
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
US20080255039A1 (en) 2004-02-27 2008-10-16 Inserm (Institut National De La Sante Et De La Recherche Medicale) Il-15 Binding Site for Il 15-Ralpha and Specific Il-15 Mutants Having Agonists/Antagonists Activity
US20080227119A1 (en) 2006-10-04 2008-09-18 Genentech, Inc. ELISA for VEGF

Non-Patent Citations (22)

* Cited by examiner, † Cited by third party
Title
BADOUAL C ET AL: "The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER REREARCH, US LNKD- DOI:10.1158/0008-5472.CAN-07-6842, vol. 68, no. 10, 15 May 2008 (2008-05-15), pages 3907 - 3914, XP002488938, ISSN: 0008-5472 *
BADOUAL ET AL.: "The Soluble a Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer", CANCER RES., vol. 68, no. 10, 2008, pages 3907 - 3914
BERNARD J ET AL: "Identification of an interleukin-15alpha receptor-binding site on human interleukin-15", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, INC, US LNKD- DOI:10.1074/JBC.M312458200, vol. 279, no. 23, 4 June 2004 (2004-06-04), pages 24313 - 24322, XP002286785, ISSN: 0021-9258 *
BESTE ET AL., PROC. NATL. ACAD. SCI., vol. 96, 1993, pages 1898 - 1903
BOUCHAUD G ET AL: "Interleukin-15 and Its Soluble Receptor Mediate the Response to Infliximab in Patients With Crohn's Disease", GASTROENTEROLOGY, ELSEVIER, PHILADELPHIA, PA, vol. 138, no. 7, 1 June 2010 (2010-06-01), pages 2378 - 2387, XP027094499, ISSN: 0016-5085, [retrieved on 20100223] *
BUDAGIAN ET AL.: "Natural Soluble Interleukin-15Ra is Generated by Cleavage That Involves the Tumor Necrosis Factor-a-converting Enzyme (TACElADAM17)", J. BIOL. CHEM., vol. 279, no. 39, pages 40368 - 40375
BULANOVA E ET AL: "Soluble interleukin (IL)-15R[alpha] is generated by alternative splicing or proteolytic cleavage and forms functional complexes with IL-15", JOURNAL OF BIOLOGICAL CHEMISTRY 20070504 AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY INC. US, vol. 282, no. 18, 4 May 2007 (2007-05-04), pages 13167 - 13179, XP002607607, DOI: DOI:10.1074/JBC.M610036200 *
CLARKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
EMBO JOURNAL, vol. 14, 1995, pages 3654 - 3663
IMMUNITY, vol. 17, no. 5, 2002, pages 537 - 47
KOHLER; MILSTEIN, NATURE, vol. 256, 1975, pages 495 - 497
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
MATSUMOTO M ET AL: "On-column refolding and characterization of soluble human interleukin-15 receptor alpha-chain produced in Escherichia coli", PROTEIN EXPRESSION AND PURIFICATION, ACADEMIC PRESS, SAN DIEGO, CA LNKD- DOI:10.1016/S1046-5928(03)00143-8, vol. 31, no. 1, 1 September 2003 (2003-09-01), pages 64 - 71, XP004454317, ISSN: 1046-5928 *
MORTIER ERWAN ET AL: "IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US LNKD- DOI:10.1084/JEM.20071913, vol. 205, no. 5, 12 May 2008 (2008-05-12), pages 1213 - 1225, XP002571967, ISSN: 0022-1007 *
MORTIER ERWAN ET AL: "IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation", THE JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, US LNKD- DOI:10.1084/JEM.20071913, vol. 205, no. 5, 12 May 2008 (2008-05-12), XP002607608, Retrieved from the Internet <URL:http://jem.rupress.org/content/suppl/2008/05/04/jem.20071913.DC1/1.html> [retrieved on 20101026] *
MORTIER ERWAN ET AL: "Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 173, no. 3, 1 August 2004 (2004-08-01), pages 1681 - 1688, XP002445753, ISSN: 0022-1767 *
MORTIER ET AL.: "IL-15R? Chaperones IL-15 to Stable Dendritic Cell Membrane Complexes that Activate NK Cells via Trans Presentation", J. EXP. MED., vol. 205, no. 5, 2008, pages 1213 - 1225
MORTIER ET AL.: "Natural, Proteolytic Release of a Soluble Form of Human IL-1 5 Receptor a-Chain that Behaves as a Specific, High Affinity IL-15 Antagonist", J. IMMUNOLOGY, vol. 173, 2004, pages 1681 - 1688
MORTIER ET AL.: "soluble Interleukin-15 Receptor a (IL-15R?)-sushi as a Selective and Potent Agonist of IL-15 Action through IL-15R?/?", J. BIOL. CHEM., vol. 281, no. 3, 2006, pages 1612 - 1619
RUCHATZ H ET AL: "SOLUBLE IL-15 RECEPTOR ALPHA-CHAIN ADMINISTRATION PREVENTS MURINE COLLAGEN-INDUCED ARTHRITIS: A ROLE FOR IL-15 IN DEVELOPMENT OF ANTIGEN-INDUCED IMMUNOPATHOLOGY", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 160, 1 January 1998 (1998-01-01), pages 5654 - 5660, XP002941876, ISSN: 0022-1767 *
TAGAYA Y ET AL., EMBO J., vol. 15, no. 18, 1996, pages 4928 - 493
WALDMANN: "The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design", NATURE REVIEW IMMUNOLOGY, vol. 6, 2006, pages 595 - 601

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109311972A (zh) * 2016-06-15 2019-02-05 美国安进公司 用于治疗乳糜泻、非乳糜泻麸质敏感和难治性乳糜泻的方法和组合物

Similar Documents

Publication Publication Date Title
Hudson et al. An immunoassay to detect human mullerian inhibiting substance in males and females during normal development
US10852302B2 (en) Method for evaluation of function of phagocyte
EP2564202B1 (fr) Détection d&#39;anticorps dirigés contre des anticorps thérapeutiques
US20090123415A1 (en) Diagnosis, treatment, and prevention of vascular disorders using il-1 autoantibodies
CN103154027A (zh) 可溶性人st-2抗体和分析法
JP2020073870A (ja) 腎疾患のためのマーカー
US20180298072A1 (en) Diagnosis of a novel autoimmune disease
JP5437633B2 (ja) モノクローナル抗体およびその用途
Louis et al. T-bet+ CD27+ CD21–B cells poised for plasma cell differentiation during antibody-mediated rejection of kidney transplants
AU2017268198C1 (en) Anti-Factor IX Padua antibodies
Reggiani et al. Focal segmental glomerular sclerosis: do not overlook the role of immune response
Rajaei et al. Evaluating the relationship between serum level of interleukin-6 and rheumatoid arthritis severity and disease activity
Buono et al. Development, analytical validation, and initial clinical evaluation of a radioimmunoassay for the measurement of soluble CD25 concentrations in canine serum
ES2425486T3 (es) Análisis de pronóstico para determinar la respuesta de células T a antígenos HLA y uso del mismo en el campo del trasplante de tejidos
WO2011031986A1 (fr) Dosages du récepteur soluble à il-15 alpha
US20050282215A1 (en) Isolated cytokine receptor LICR-2
Kim et al. Clinical significance of classification of Graves’ disease according to the characteristics of TSH receptor antibodies
CN114270191A (zh) 炎症性肠病诊断方法、诊断探针和诊断试剂盒
EP2923205A1 (fr) Analyse de la maladie de still de l&#39;adulte (msa)
US11999798B2 (en) Anti-factor IX padua antibodies
Chouman et al. Characterization of new anti-IL-6 antibodies revealed high potency candidates for intracellular cytokine detection and specific targeting of IL-6 receptor binding sites
JP2019211230A (ja) ヒト由来サンプルにおける可溶型ｔｌｒ７の分析
JP3045172B2 (ja) Ｉｌ―６レセプターを利用したヒトｉｌ―６の化学的測定法及びそのためのキット
Meilof Autoantibodies against small cytoplasmic ribonucleoproteins: the anti-Ro/SS-A and anti-La/SS-B autoimmune response: A review of autoantibody detection, autoantigen composition, autoantibody-disease associations and possible etiologic mechanisms
Fernandez Variable IL-2Rβ Expression and Organization in Signaling and Disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10755280

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10755280

Country of ref document: EP

Kind code of ref document: A1